Modulating effects of the probiotic <em>Lactococcus lactis</em> on the hepatic fibrotic process induced by CCl<sub>4</sub> in Wistar rats

Delgado‑Venegas,Catalina Soledad; Martínez‑Hernández,Sandra Luz; Cervantes‑García,Daniel; Montes de Oca‑Luna,Roberto; Loera‑Arias,María de Jesús; Mata‑Martínez,María Guadalupe; Ventura‑Juárez,Javier; Muñoz‑Ortega,Martín Humberto

doi:10.3892/etm.2021.9770

Modulating effects of the probiotic Lactococcus lactis on the hepatic fibrotic process induced by CCl₄ in Wistar rats

Authors:
- Catalina Soledad Delgado‑Venegas
- Sandra Luz Martínez‑Hernández
- Daniel Cervantes‑García
- Roberto Montes de Oca‑Luna
- María de Jesús Loera‑Arias
- María Guadalupe Mata‑Martínez
- Javier Ventura‑Juárez
- Martín Humberto Muñoz‑Ortega
View Affiliations

Affiliations: Center for Basic Sciences, Department of Morphology, Autonomous University of Aguascalientes, Aguascalientes 20131, Mexico, National Council of Science and Technology, Center for Basic Sciences, Department of Microbiology, Autonomous University of Aguascalientes, Aguascalientes 20131, Mexico, Faculty of Medicine, Department of Histology, Autonomous University of Nuevo Léon, Monterrey, Nuevo León, 64460, Mexico, Center of Basic Sciences, Department of Chemistry, Autonomous University of Aguascalientes, Aguascalientes 20131, Mexico
Published online on: February 10, 2021 https://doi.org/10.3892/etm.2021.9770
Article Number: 339
Copyright: © Delgado‑Venegas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic cirrhosis is a chronic disease that affects one fifth of the World's population and is the third leading cause of death in Mexico. Attempts have been made to develop treatments for this hepatic cirrhosis, which include manipulating the intestinal microbiota and thus decreasing the early inflammatory response. The microbiota is reportedly altered in patients with cirrhosis. Due to its immunomodulatory properties and its ability to survive in the gastrointestinal tract, Lactococcus lactis (L. lactis) has been used as a therapeutic measure in inflammatory disorders of the colon. The objective of the present study was to evaluate the efficacy of the L. lactis probiotic NZ9000 in preventing tetrachloromethane (CCl₄)‑induced experimental hepatic fibrosis. The following 4 groups were included in the experimental stage (n=5): i) Control group; ii) L. lactis group; iii) CCl₄ group; and iv) L. lactis‑CCl₄ group. For the first 2 weeks, L. lactis was orally administered to the L. lactis and L. lactis‑CCl₄ groups; CCl₄ was then peritoneally administered to the lactis‑CCl₄ group for a further 4 weeks (in addition to the probiotic), while the L. lactis group received the probiotic only. For the CCl4 group, CCl4 was administered for 4 weeks. The experimental groups were all compared with the control group and the L. lactis + CCl₄ group. Tissue samples were analyzed histologically and biochemically, and the gene expression levels of interleukin (IL)‑1, IL‑10 and forkhead box protein P3 (FoxP3) were determined. L. lactis decreased hepatic cirrhosis by preventing steatosis and fibrosis, and by reducing the levels of AST and ALT. Subchronic CCl₄ injury induced upregulation of the IL‑1β gene in the liver, which was decreased by L. lactis. It was also found that the group treated with L. lactis showed increased expression of Foxp3 in the liver and IL‑10 in the gut. These results suggested that oral administration of L. lactis may be a potential probiotic to prevent or protect against CCl₄‑induced liver injury.

View Figures

View References

1	Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008.PubMed/NCBI View Article : Google Scholar
2	Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C and Sgonc R: The immunology of fibrosis: Innate and adaptive responses. Trends Immunol. 31:110–119. 2010.PubMed/NCBI View Article : Google Scholar
3	Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R and Wolfram D: The immunology of fibrosis. Annu Rev Immunol. 31:107–135. 2013.PubMed/NCBI View Article : Google Scholar
4	Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol. 214:199–210. 2008.PubMed/NCBI View Article : Google Scholar
5	Kershenobich Stalnikowitz D and Weissbrod AB: Liver fibrosis and inflammation. A review. Ann Hepatol. 2:159–163. 2003.PubMed/NCBI
6	Romanelli RG and Stasi C: Recent advancements in diagnosis and therapy of liver cirrhosis. Curr Drug Targets. 17:1804–1817. 2016.PubMed/NCBI View Article : Google Scholar
7	Khan H, Ullah H and Nabavi SM: Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem Toxicol. 124:182–191. 2019.PubMed/NCBI View Article : Google Scholar
8	Serna-Salas SA, Navarro-González YD, Martínez-Hernández SL, Barba-Gallardo LF, Sánchez-Alemán E, Aldaba-Muruato LR, Macías-Pérez JR, Ventura-Juárez J and Muñoz-Ortega MH: Doxazosin and carvedilol treatment improves hepatic regeneration in a hamster model of cirrhosis. Biomed Res Int. 2018(4706976)2018.PubMed/NCBI View Article : Google Scholar
9	Khawar MB, Azam F, Sheikh N and Abdul Mujeeb K: How does interleukin-22 mediate liver regeneration and prevent injury and fibrosis? J Immunol Res. 2016(2148129)2016.PubMed/NCBI View Article : Google Scholar
10	Abd-Elgawad H, Abu-Elsaad N, El-Karef A and Ibrahim T: Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Can J Physiol Pharmacol. 94:779–787. 2016.PubMed/NCBI View Article : Google Scholar
11	Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, et al: Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 60:940–947. 2014.PubMed/NCBI View Article : Google Scholar
12	Moraes-Filho JP and Quigley EM: The intestinal microbiota and the role of probiotics in irritable bowel syndrome: A review. Arq Gastroenterol. 52:331–338. 2015.PubMed/NCBI View Article : Google Scholar
13	Festen EAM, Szperl AM, Weersma RK, Wikmenga C and Wapenaar MC: Inflammatory bowel disease and celiac disease: Overlaps in the pathology and genetics, and their potential drug targets. Endocr Metab Immune Disord Drug Targets. 9:199–218. 2009.PubMed/NCBI View Article : Google Scholar
14	Lee NK, Kim SY, Han KJ, Eom SJ and Paik HD: Probiotic potential of Lactobacillus strains with anti-allergic effects from kimchi for yogurt starters. LWT Food Sci Technol. 58:130–134. 2014.
15	Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ and Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 47:79–87. 2000.PubMed/NCBI View Article : Google Scholar
16	Fabia R, Ar'Rajab A, Johansssib ML, Willén R, Andersson R, Molin G and Bengmark S: The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol. 28:155–162. 1993.PubMed/NCBI View Article : Google Scholar
17	Mao Y, Nobaeck S, Kasravi B, Adawi D, Stenram U, Molin G and Jeppsson B: The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 111:334–344. 1996.PubMed/NCBI View Article : Google Scholar
18	Bhat M, Arendt BM, Bhat V, Renner EL, Humar A and Allard JP: Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol. 8:1128–1136. 2016.PubMed/NCBI View Article : Google Scholar
19	Parapouli M, Delbès-Paus C, Kakouri A, Koukkou AI, Montel MC and Samelis J: Characterization of a wild, novel nisin a-producing Lactococcus strain with an L. lactis subsp. cremoris genotype and an L. lactis subsp. lactis phenotype, isolated from Greek raw milk. Appl Environ Microbiol. 79:3476–3484. 2013.PubMed/NCBI View Article : Google Scholar
20	Duwat P, Sourice S, Cesselin B, Lamberet G, Vido K, Gaudu P, Le Loir Y, Violet F, Loubière P and Gruss A: Respiration capacity of the fermenting bacterium Lactococcus lactis and its positive effects on growth and survival. J Bacteriol. 183:4509–4516. 2001.PubMed/NCBI View Article : Google Scholar
21	Garrigues C, Loubiere P, Lindley ND and Cocaign-Bousquet M: Control of the shift from homolactic acid to mixed-acid fermentation in Lactococcus lactis: Predominant role of the NADH/NAD+ ratio. J Bacteriol. 179:5282–5287. 1997.PubMed/NCBI View Article : Google Scholar
22	Daniel C, Repa A, Wild C, Pollak A, Pot B, Breiteneder H, Wiedermann U and Mercenier A: Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy. 61:812–819. 2006.PubMed/NCBI View Article : Google Scholar
23	Alvarenga DM, Perez DA, Gomes-Santos AC, Miyoshi A, Azevedo V, Coelho-Dos-Reis JG, Martins-Filho OA, Faria AM, Cara DC and Andrade MC: Previous ingestion of Lactococcus lactis by ethanol-treated mice preserves antigen presentation hierarchy in the gut and oral tolerance susceptibility. Alcohol Clin Exp Res. 39:1453–1464. 2015.PubMed/NCBI View Article : Google Scholar
24	Marinho FA, Pacífico LG, Miyoshi A, Azevedo V, Le Loir Y, Guimarães VD, Langella P, Cassali GD, Fonseca CT and Oliveira SC: An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model. Clin Exp Allergy. 40:1541–1551. 2010.PubMed/NCBI View Article : Google Scholar
25	Nishitani Y, Tanoue T, Yamada K, Ishida T, Yoshida M, Azuma T and Mizuno M: Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int Immunopharmacol. 9:1444–1451. 2009.PubMed/NCBI View Article : Google Scholar
26	Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, Pereira VB, de Azevedo M, Moraes K, et al: Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis. Gut Pathog. 6(33)2014.PubMed/NCBI View Article : Google Scholar
27	Ballal SA, Veiga P, Fenn K, Michaud M, Kim JH, Gallini CA, Glickman JN, Quéré G, Garault P, Béal C, et al: Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons. Proc Natl Acad Sci USA. 112:7803–7808. 2015.PubMed/NCBI View Article : Google Scholar
28	Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W and Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 289:1352–1355. 2020.PubMed/NCBI View Article : Google Scholar
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
30	Williams LM, Ricchetti G, Sarma U, Smallie T and Foxwell BM: Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology. 113:281–292. 2004.PubMed/NCBI View Article : Google Scholar
31	Aller MA, Vara E, Garcia C, Palma MD, Arias JL, Nava MP and Arias J: Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm. 2005:101–111. 2005.PubMed/NCBI View Article : Google Scholar
32	US National Institutes of Health: NIH human microbiome project. https://www.hmpdacc.org/overview/.
33	Kibe R, Sakamoto M, Yokota H, Ishikawa H, Aiba Y, Koga Y and Benno Y: Movement and fixation of intestinal microbiota after administration of human feces to germfree mice. Appl Environ Microbiol. 71:3171–3178. 2005.PubMed/NCBI View Article : Google Scholar
34	Chen H, Xia Y, Zhu S, Yang J, Yao J, Di J, Liang Y, Gao R, Wu W, Yang Y, et al: Lactobacillus plantarum LP-nlly alters the gut flora and attenuates colitis by inducing microbiome alteration in interleukin-10 knockout mice. Mol Med Rep. 16:5979–5985. 2017.PubMed/NCBI View Article : Google Scholar
35	Macpherson AJ and Uhr T: Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 303:1662–1665. 2004.PubMed/NCBI View Article : Google Scholar
36	Liu X, Lou J, Chen Y and Duan Z: Changes of regulatory T cells related to CCl₄-induced liver fibrosis in mice. Zhonghua Gan Zang Bing Za Zhi. 22:277–280. 2014.PubMed/NCBI View Article : Google Scholar : (In Chinese).
37	Rios DA, Valva P, Casciato PC, Frias S, Soledad Caldirola M, Gaillard MI, Bezrodnik L, Bandi J, Galdame O, et al: Chronic hepatitis C liver microenvironment: Role of the Th17/Treg interplay related to fibrogenesis. Sci Rep. 7(13283)2017.PubMed/NCBI View Article : Google Scholar
38	Schiffin EJ, Brassart D, Servin AL, Rochat F and Donnet-Hughes A: Immune modulation of blood leukocytes in humans by lactic acid bacteria: Criteria for strain selection. Am J Clin Nutr. 66:515S–520S. 1997.PubMed/NCBI View Article : Google Scholar